Amgen’s experimental KRAS-blocking drug is showing minimal tumor-shrinking effects in patients with advanced colorectal cancer, raising new doubts about whether the drug can be broadly effective against different types of solid tumors.

The drug, known as AMG 510, has generated significant interest since the release of data showing its potential to shrink tumors in lung cancer patients. But data presented Saturday at this year’s meeting of the European Society for Medical Oncology were more disappointing. Of 29 patients with advanced colorectal cancer treated with AMG 510 in Amgen’s Phase 1 clinical trial, one patient showed partial tumor shrinkage. That’s a response rate of 3%.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy